157.37
5.73 (3.78%)
| Penutupan Terdahulu | 151.64 |
| Jumlah Dagangan | 2,036,897 |
| Harga / Pendapatan (P/E Ke hadapan) | 11.86 |
| Harga / Jualan (P/S) | 4.17 |
| Harga / Buku (P/B) | 5.63 |
| Julat 52 Minggu |
| Margin Keuntungan | -11.49% |
| Margin Operasi (TTM) | 3.04% |
| EPS Cair (TTM) | -2.11 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 20.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 2,358.25% |
| Nisbah Semasa (MRQ) | 3.04 |
| Aliran Tunai Operasi (OCF TTM) | -45.11 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 223.09 M |
| Pulangan Atas Aset (ROA TTM) | -1.79% |
AISkor Stockmoo
| Nilai 35% | -0.5 |
| AI Insight info | NA |
| Penilaian Relatif info | NA |
| Kesihatan Kewangan info | -0.5 |
| Masa 35% | -0.5 |
| AI Technical info | NA |
| Osilator Teknikal info | -2.5 |
| Purata Bergerak Teknikal info | 2.5 |
| Wang Pintar 30% | 0.0 |
| Konsensus Penganalisis info | 0.0 |
| Aktiviti Orang Dalam info | NA |
| Sentimen Berita info | NA |
| Persekitaran | ×1.21 |
| Persekitaran Makro info | -3.3 |
| Sektor berbanding Pasaran (6B) | -23.0% |
| Persetujuan Tonggak | ×1.25 |
| Tidak dikira dalam skor | |
| Volatiliti Harga info | 4.3 |
| Skor Akhir | -0.53 |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menaik |
| Biotechnology (Global) | Bercampur | Menaik | |
| Stok | Alnylam Pharmaceuticals, Inc. | Bercampur | Menurun |
Saham Serupa
| Stok | Modal Pasaran | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| ALNY | - | - | - | 5.63 |
| BMRN | - | - | - | 1.77 |
| ARGX | - | - | - | 7.26 |
| SMMT | - | - | - | 25.24 |
| WVE | - | - | - | 1.67 |
| NAMS | - | - | - | 3.64 |
|
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam’s commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam’s partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Mid Growth |
| % Dimiliki oleh Orang Dalam | 3.81% |
| % Dimiliki oleh Institusi | 97.56% |
Tiada data dalam julat masa ini.
Tiada data dalam julat masa ini.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |